Pancreatic Adenocarcinoma research hub
17 indexed studies · 11 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients with Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)
This study is testing two new targeted drugs, zoldonrasib and daraxonrasib, for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. Researchers want to see if this combination works better and is kinder than standard chemotherapy at slowing the cancer down and helping people live longer.
Austria · Netherlands · Germany - recruitingPHASE3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is looking at a new drug, daraxonrasib, for people with pancreatic cancer that has spread. It compares daraxonrasib alone, or with standard chemotherapy (gemcitabine and nab-paclitaxel), against standard chemotherapy by itself. The aim is to see if the new treatments can help people live longer and stop the cancer from growing.
United States · Australia · Austria - recruitingPHASE3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is testing a new medicine, atebimetinib, alongside standard chemotherapy for pancreatic cancer that has spread. We want to see if this combination works better and is safe for patients who haven't had treatment before.
United States · Australia · Georgia - active not recruitingPHASE2
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
This study looks at new drug combinations for certain advanced cancers. It aims to understand how these drugs affect cancer at a genetic level and in the body. It combines an immunotherapy drug with another type of cancer drug.
Canada - active not recruitingPHASE1
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
This study tests new ways to treat advanced pancreatic cancer. It combines a targeted drug (anetumab ravtansine) with immune-boosting medicines (nivolumab, ipilimumab) and standard chemotherapy (gemcitabine) to see if these combinations are safe and effective.
United States · Canada - recruitingPHASE2
Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
This study looks at giving chemotherapy before surgery for a type of pancreatic cancer that is tricky to remove. Doctors want to see if this approach is practical and safe, and if it helps patients better prepare for surgery.
Canada - active not recruiting
Biological and Clinical Database for Pancreatic Adenocarcinoma
This study is building a vital collection of biological samples, like blood and tissue, and medical information from patients with pancreatic cancer. Its goal is to help scientists in France better understand this cancer, improve diagnosis, and find more effective treatments.
France - recruitingPHASE3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
This study is testing a new drug called zoldonrasib, combined with standard chemotherapy, for people with pancreatic cancer that has spread. It compares this combination to chemotherapy alone, to see if it helps people live longer or stops the cancer from growing for longer. It focuses on a specific type of cancer gene.
United States · United Kingdom - recruitingPHASE1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study is testing a new drug, PF-08046054/SGN-PDL1V, alone and with an existing medicine called pembrolizumab, for various advanced cancers. Researchers want to see how safe it is and if it has any effect on the cancer. It's a very early stage study.
United States · Belgium · Canada - active not recruitingNA
The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer
This study looks at a surgical technique for pancreatic cancer. It aims to see if a specific way of dissecting around a blood vessel (the SMA) during surgery helps remove all cancer cells, potentially improving patient outcomes.
United Kingdom - recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
This study looks at a new blood test to find cancer early in people who have already been treated for certain cancers. It aims to see if this test can tell when cancer might come back, helping doctors give the best care sooner.
United States · France · Germany - not yet recruiting
Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas
This study looks at a new test called proteomic profiling. It aims to help doctors tell the difference between two types of cancer, pancreatic and biliary adenocarcinoma. Because these cancers look similar, it's sometimes hard to know which one it is, which affects treatment choices.
France - active not recruitingNA
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
This study is testing a new radiation treatment called DaRT for advanced pancreatic cancer. It involves placing small devices directly into the tumour to deliver radiation. Doctors want to see if it's safe and effective for people whose cancer can't be removed by surgery.
Canada - recruitingPHASE1, PHASE2
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
This study is testing a new drug, BMS-986340, by itself and with other treatments for different advanced cancers. Researchers want to find the safest dose and see how well it works. This is the first time BMS-986340 has been tried in people.
United States · Australia · Canada - recruitingPHASE1
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
This study is looking at a new combination treatment for advanced pancreatic cancer with a specific genetic change (KRAS G12C). It combines a drug called sotorasib with standard chemotherapy to see how safe and well it's tolerated in patients.
France · Spain - recruitingPHASE1, PHASE2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
This study is looking at a new drug, GTAEXS617, for people with advanced solid tumours, including certain types of breast, lung, head and neck, and ovarian cancers. We want to see how safe it is, how the body handles it, and if it can shrink tumours.
United States · Belgium · United Kingdom - recruitingPHASE1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
This study is looking at a new medicine called PF-08046876 for people with advanced cancers like bladder, lung, head & neck, oesophageal, or pancreatic cancer. It checks how safe the medicine is and how well it works. The medicine is given through a drip.
United States · Canada · China